After selling a building, a marketed product and a subsidiary during the past year, AEterna Zentaris Inc. continued its asset monetization strategy by selling its Cetrotide (cetrorelix) royalties to Cowen Healthcare Royalty Partners LP in exchange for $52.5 million. (BioWorld Today) Read More